alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorCelyad Oncology SA
About this trial
The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy
Eligibility criteria
Qualifiers
Histologically proven metastatic adenocarcinoma of the colon or rectum.
Confirmed metastatic unresectable adenocarcinoma of the colon or the rectum.
Recurrent/progressing disease after at least one line of systemic therapy for metastatic disease.
Unequivocal and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).
Disqualifiers
The patient has a confirmed or history of tumor involvement in the central nervous system (CNS).
Any non-cancer-directed investigational agent within 3 weeks before the planned day for the first CYAD-101 administration.
Filgrastim (Granulocyte-Colony-Stimulating Factor [G-CSF]) or similar growth factors within 7 days before the planned day for the first CYAD-101 administration.
Prior allogeneic stem cell transplantation, chimeric antigen receptor therapy or other genetically modified T-cell therapy.
Trial design
Treatments tested in this trial
- CYAD-101
- FOLFOX
- FOLFIRI
Treatment groups
49 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov